Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier SA

www.servier.com

Latest From Servier SA

In A Record Year For US FDA Approvals, Pfizer Came Out On Top

FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders. 
Approvals Drug Review

Scrip’s Top Five Stories Of 2018

A look back at the Scrip stories that piqued the most interest for our readers in 2018. 

Companies Commercial

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.

ImmunoOncology Research and Development Strategies

Keeping Track Of The US FDA's Final Approvals Of 2018

A roundup of the US FDA's drug approvals in the final weeks of 2018.
Approvals Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register